Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Over the past 20 years, substantial advances have been made in the treatment of patients with metastatic colorectal cancer (mCRC). In particular, there is now a wide range of options for the front-line treatment of mCRC. Sophisticated molecular technologies have been developed to identify novel prognostic and predictive biomarkers for CRC. DNA sequencing technology has made remarkable advances in recent years, primarily as a result of the development of next-generation sequencing and whole exome sequencing, which are powerful new tools for the discovery of predictive molecular biomarkers to facilitate the delivery of personalized medicine. In addition to tumor tissue, recent efforts have focused on analyzing circulating tumor DNA in peripheral blood. Herein, we review the evolution of standard chemotherapy and targeted therapy strategies for the treatment of mCRC in the front-line setting, the molecular technologies that are presently being used to facilitate our ability to practice individualized medicine, and the practical aspects of applying molecular biomarkers to everyday clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, an improved surgical resection rate was found with triplet therapy [143].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [143]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citationVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crinò, L., Benedetti, G., Evangelista, W., Fanchini, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0928 · Cited by 1,241
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 797
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 635
Bokemeyer, C., Cutsem, E. V., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., & Köhne, C.-H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.057 · Cited by 585
Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Self-citationPietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.19 · Cited by 401
Vauthey, J.-N., Zimmitti, G., Kopetz, S. E., Shindoh, J., Chen, S. S., Andreou, A., Curley, S. A., Aloia, T. A., & Maru, D. M. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182a5025a · Cited by 376
Brannon, A., Vakiani, E., Sylvester, B. E., Scott, S. N., McDermott, G., Shah, R. H., Kania, K., Viale, A., Oschwald, D. M., Vacic, V., et al. (2014) · Genome Biology · doi:10.1186/preaccept-1207406452128377 · Cited by 372
Self-citationRowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., Cercek, A., Kemeny, N., D'Angelica, M., Viale, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2994 · Cited by 282
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Self-citationStadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., Yaeger, R., Segal, N. H., Varghese, A. M., Reidy-Lagunes, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1067 · Cited by 234
Self-citationHong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Yaeger, R., Cercek, A., Chou, J. F., Sylvester, B. E., Kemeny, N. E., Hechtman, J. F., Ladanyi, M., Rosen, N., Weiser, M. R., Capanu, M., et al. (2014) · Cancer · doi:10.1002/cncr.28729 · Cited by 203
Self-citationMasi, G., Vasile, E., Loupakis, F., Cupini, S., Fornaro, L., Baldi, G., Salvatore, L., Cremolini, C., Stasi, I., Brunetti, I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq456 · Cited by 188
Yaeger, R., Cowell, E., Chou, J. F., Gewirtz, A. N., Borsu, L., Vakiani, E., Solit, D. B., Rosen, N., Capanu, M., Ladanyi, M., et al. (2015) · Cancer · doi:10.1002/cncr.29196 · Cited by 187
Self-citationCremolini, C., Bartolomeo, M. D., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv290 · Cited by 173
Ducreux, M., Bennouna, J., Hebbar, M., Ychou, M., Lledo, G., Conroy, T., Adenis, A., Faroux, R., Rebischung, C., Bergougnoux, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25369 · Cited by 166
First-line chemotherapy for mCRC—a review and evidence-based algorithm
Cremolini, C., Schirripa, M., Antoniotti, C., Moretto, R., Salvatore, L., Masi, G., Falcone, A., & Loupakis, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.129 · Cited by 162
Martin, V, Landi, L., Molinari, F., Fountzilas, G., Geva, R., Riva, A., Saletti, P., De Dosso, S., Spitale, A., Tejpar, S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.4 · Cited by 156
Ramanathan, R. K., Hwang, J. J., Zamboni, W. C., Sinicrope, F. A., Safran, H., Wong, M. K., Earle, M., Brufsky, A., Evans, T., Troetschel, M., et al. (2004) · Cancer Investigation · doi:10.1081/cnv-200039645 · Cited by 136
Clancy, C., Burke, J. P., Kalady, M. F., & Coffey, J. C. (2013) · Colorectal Disease · doi:10.1111/codi.12427 · Cited by 133
Morris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Zheng, G., Tseng, L.-H., Chen, G., Haley, L., Illei, P., Gocke, C. D., Eshleman, J. R., & Lin, M.-T. (2015) · BMC Cancer · doi:10.1186/s12885-015-1811-y · Cited by 103
Fornaro, L., Lonardi, S., Masi, G., Loupakis, F., Bergamo, F., Salvatore, L., Cremolini, C., Schirripa, M., Vivaldi, C., Aprile, G., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt165 · Cited by 103
Kalofonos, H. P., Aravantinos, G., Kosmidis, P., Papakostas, P., Economopoulos, T., Dimopoulos, M. A., Skarlos, D. V., Bamias, A., Pectasides, D. G., Chalkidou, S., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi193 · Cited by 86
Ducreux, M. P., Adenis, A., Pignon, J., François, É., Chauffert, B., Ichante, J.-L., Boucher, É., Ychou, M., Pierga, J., Montoto-Grillot, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.011 · Cited by 85
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
Amatu, A., Somaschini, A., Cerea, G., Bosotti, R., Valtorta, E., Buonandi, P., Marrapese, G., Veronese, S., Luo, D., Hornby, Z., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.401 · Cited by 82
Passot, G., Denbo, J. W., Yamashita, S., Kopetz, S., Chun, Y. S., Maru, D. M., Overman, M. J., Brudvik, K. W., Conrad, C. H., Aloia, T. A., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.07.032 · Cited by 64
Expanded RAS: Refining the Patient Population
Atreya, C. E., Corcoran, R. B., & Kopetz, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9325 · Cited by 63
Self-citationSaridaki, Z., Androulakis, N., Vardakis, N., Vamvakas, L., Kabouraki, E., Kalbakis, K., Hatzidaki, D., Voutsina, A., Mavroudis, D., Georgoulias, V., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.509 · Cited by 62
Resistance to EGFR-Targeted Therapy: A Family Affair
Vlacich, G., & Coffey, R. J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.006 · Cited by 61
Hechtman, J. F., Zehir, A., Yaeger, R., Wang, L., Middha, S., Zheng, T., Hyman, D. M., Solit, D., Arcila, M. E., Borsu, L., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0392-t · Cited by 50
Self-citationFirst-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm
Cremolini, C., Antoniotti, C., Moretto, R., Masi, G., & Falcone, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.219 · Cited by 33
Guo, Y., Shi, M., Shen, X., Chen, Y., Yang, L., & Zhang, J. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.12.004 · Cited by 29
Atreya, C. E., Greene, C., McWhirter, R. M., Ikram, N. S., Allen, I. E., Van Loon, K., Venook, A. P., Yeh, B. M., & Behr, S. C. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0165 · Cited by 21
Self-citation
Research works printed but not linked: 8
- Weinberg BA, 2016, Clin Adv Hematol Oncol, 14, 116
- Venook A, 2006, J Clin Oncol
- 10.1186/s13059-014-0454-7 · doi:10.1186/s13059-014-0454-7 · Paper page
- Raghav KPS, 2016, J Clin Oncol, 34
- Sartore-Bianchi A, 2015, J Natl Cancer Inst, 108, djv306
- Seligmann JF, Ann Oncol
- Sehdev A, 2016, Discov Med, 21, 341
- Corcoran R, 2016, Ann Onco, 27, vi1
Cited by
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota
Sougiannis, A. T., VanderVeen, B. N., Enos, R. T., Velázquez, K. T., Bader, J. E., Carson, M. S., Chatzistamou, I., Walla, M. D., Pena, M. M., Kubinak, J. L., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.02.020 · Cited by 152
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 132
The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials
Hervieu, C., Christou, N., Battu, S., & Mathonnet, M. (2021) · Cancers · doi:10.3390/cancers13051092 · Cited by 121
Angiogenin promotes colorectal cancer metastasis via tiRNA production
Li, S., Shi, X., Chen, M., Xu, N., Sun, D., Bai, R., Chen, H., Ding, K., Sheng, J., & Xu, Z. (2019) · International Journal of Cancer · doi:10.1002/ijc.32245 · Cited by 112
Shen, X., Hu, X., Mao, J., Wu, Y., Liu, H., Shen, J., Yu, J., & Chen, W. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2254-1 · Cited by 95
Metadata
- Authors
- Atreya, C. E., Yaeger, R., & Chu, E.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2017-05
- Volume
- 37
- Issue
- 37
- Pages
- 246-256
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4244654711
- Cited by
- 35
- References
- 66
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 8 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 1
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K08CA175153)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, systemic therapy, first-line therapy, targeted therapy, predictive biomarkers, prognostic factors, next-generation sequencing, exome sequencing, circulating tumor DNA, personalized medicine, chemotherapy
- MeSH terms
- Humans, Neoplastic Cells, Circulating, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Precision Medicine, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.